Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company offers enoxaparin, a low molecular weight heparin that is used as an anticoagulant for the prevention and treatment of deep vein thrombosis; naloxone for opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; procainamide for documented ventricular arrhythmias; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy. In addition, the company manufactures and distributes recombinant human and porcine insulins. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. Amphastar Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone909-980-9484
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$240.18 million
Profitability
Miscellaneous
Employees1,644
Next Earnings Date3/11/2019 (Estimated)
OptionableOptionable
Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions
What is Amphastar Pharmaceuticals' stock symbol?
Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."
How will Amphastar Pharmaceuticals' stock buyback program work?
Amphastar Pharmaceuticals announced that its Board of Directors has authorized a stock buyback program on Thursday, August 10th 2017, which authorizes the company to buyback $20,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to buy up to 2.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company's board of directors believes its shares are undervalued.
How were Amphastar Pharmaceuticals' earnings last quarter?
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) released its quarterly earnings data on Thursday, November, 8th. The company reported $0.12 EPS for the quarter, topping the Zacks' consensus estimate of $0.11 by $0.01. The firm earned $75.54 million during the quarter, compared to analyst estimates of $76.84 million. Amphastar Pharmaceuticals had a negative net margin of 2.33% and a positive return on equity of 2.80%. The business's revenue was up 30.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.07 earnings per share. View Amphastar Pharmaceuticals' Earnings History.
When is Amphastar Pharmaceuticals' next earnings date?
What price target have analysts set for AMPH?
4 Wall Street analysts have issued 12 month price targets for Amphastar Pharmaceuticals' stock. Their forecasts range from $19.00 to $26.00. On average, they anticipate Amphastar Pharmaceuticals' stock price to reach $23.3333 in the next year. This suggests that the stock has a possible downside of 3.5%. View Analyst Price Targets for Amphastar Pharmaceuticals.
What is the consensus analysts' recommendation for Amphastar Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amphastar Pharmaceuticals.
Has Amphastar Pharmaceuticals been receiving favorable news coverage?
Media headlines about AMPH stock have trended somewhat positive on Thursday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amphastar Pharmaceuticals earned a media sentiment score of 0.6 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
Who are some of Amphastar Pharmaceuticals' key competitors?
Some companies that are related to Amphastar Pharmaceuticals include GW Pharmaceuticals PLC- (GWPH), TESARO (TSRO), Taro Pharmaceutical Industries (TARO), Amneal Pharmaceuticals (AMRX), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Blueprint Medicines (BPMC), Emergent Biosolutions (EBS), Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Ultragenyx Pharmaceutical (RARE) and Global Blood Therapeutics (GBT).
What other stocks do shareholders of Amphastar Pharmaceuticals own?
Who are Amphastar Pharmaceuticals' key executives?
Amphastar Pharmaceuticals' management team includes the folowing people:
- Dr. Ziping Luo, Chairman, Chief Scientist & COO (Age 69)
- Dr. Yongfeng Zhang, CEO, Chief Science Officer & Director (Age 72)
- Mr. Jason B. Shandell, Pres & Director (Age 45)
- Mr. William J. Peters, CFO, Treasurer & Sr. VP of Fin. (Age 51)
- Mr. Rong Zhou, Exec. VP of Production Center (Age 60)
Who are Amphastar Pharmaceuticals' major shareholders?
Amphastar Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.86%), Dimensional Fund Advisors LP (4.12%), Northern Trust Corp (1.03%), Bank of New York Mellon Corp (0.97%), Geode Capital Management LLC (0.92%) and Rothschild & Co. Asset Management US Inc. (0.73%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Physics & Chemistry La Applied, Richard K Prins, Richard Koo, Rong Zhou, Stephen B Shohet, William J Peters and Yakob Liawatidewi. View Institutional Ownership Trends for Amphastar Pharmaceuticals.
Which major investors are selling Amphastar Pharmaceuticals stock?
AMPH stock was sold by a variety of institutional investors in the last quarter, including Mackay Shields LLC, BlackRock Inc., Barclays PLC, Citigroup Inc., KBC Group NV, MetLife Investment Advisors LLC, Dimensional Fund Advisors LP and Northern Trust Corp. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Physics & Chemistry La Applied, Richard K Prins, Richard Koo, Rong Zhou, William J Peters and Yakob Liawatidewi. View Insider Buying and Selling for Amphastar Pharmaceuticals.
Which major investors are buying Amphastar Pharmaceuticals stock?
AMPH stock was bought by a variety of institutional investors in the last quarter, including Martingale Asset Management L P, Assenagon Asset Management S.A., Millennium Management LLC, Bessemer Group Inc., Geode Capital Management LLC, Squarepoint Ops LLC, Bank of New York Mellon Corp and Two Sigma Investments LP. View Insider Buying and Selling for Amphastar Pharmaceuticals.
How do I buy shares of Amphastar Pharmaceuticals?
Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amphastar Pharmaceuticals' stock price today?
One share of AMPH stock can currently be purchased for approximately $24.19.
How big of a company is Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals has a market capitalization of $1.12 billion and generates $240.18 million in revenue each year. The company earns $4.50 million in net income (profit) each year or $0.38 on an earnings per share basis. Amphastar Pharmaceuticals employs 1,644 workers across the globe.
What is Amphastar Pharmaceuticals' official website?
How can I contact Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]
MarketBeat Community Rating for Amphastar Pharmaceuticals (NASDAQ AMPH)
MarketBeat's community ratings are surveys of what our community members think about Amphastar Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
